ZA200300903B - Combinations of dalfopristine/quinupristine with cefpirome. - Google Patents
Combinations of dalfopristine/quinupristine with cefpirome. Download PDFInfo
- Publication number
- ZA200300903B ZA200300903B ZA200300903A ZA200300903A ZA200300903B ZA 200300903 B ZA200300903 B ZA 200300903B ZA 200300903 A ZA200300903 A ZA 200300903A ZA 200300903 A ZA200300903 A ZA 200300903A ZA 200300903 B ZA200300903 B ZA 200300903B
- Authority
- ZA
- South Africa
- Prior art keywords
- cefpirome
- dalfopristine
- quinupristine
- combination
- doses
- Prior art date
Links
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 title claims description 39
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 title claims description 38
- 229960000466 cefpirome Drugs 0.000 title claims description 38
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 title claims description 31
- 238000001802 infusion Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000009097 single-agent therapy Methods 0.000 description 7
- 206010014665 endocarditis Diseases 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 5
- 229940020707 synercid Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical class C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 108010063483 Streptogramin Group A Proteins 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 108010063479 Streptogramin Group B Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- RKTNPKZEPLCLSF-GNERTXCBSA-N OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 RKTNPKZEPLCLSF-GNERTXCBSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002838 cefpirome sulfate Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002289 effect on microbe Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical group N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thyristors (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0010245A FR2812549B1 (fr) | 2000-08-03 | 2000-08-03 | Associations dalfopristine/quinupristine avec le cefpirome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300903B true ZA200300903B (en) | 2003-11-10 |
Family
ID=8853264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300903A ZA200300903B (en) | 2000-08-03 | 2003-01-31 | Combinations of dalfopristine/quinupristine with cefpirome. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7005416B2 (es) |
| EP (1) | EP1313500B1 (es) |
| JP (1) | JP2004505926A (es) |
| KR (1) | KR100808715B1 (es) |
| CN (1) | CN1256982C (es) |
| AR (1) | AR033992A1 (es) |
| AT (1) | ATE279204T1 (es) |
| AU (2) | AU2001284095B2 (es) |
| BR (1) | BR0112897A (es) |
| CA (1) | CA2418023A1 (es) |
| CZ (1) | CZ2003290A3 (es) |
| DE (1) | DE60106463T2 (es) |
| DK (1) | DK1313500T3 (es) |
| EA (1) | EA007713B1 (es) |
| ES (1) | ES2230358T3 (es) |
| FR (1) | FR2812549B1 (es) |
| HK (1) | HK1058305A1 (es) |
| HU (1) | HU227455B1 (es) |
| IL (1) | IL154237A0 (es) |
| MX (1) | MXPA03000959A (es) |
| NO (1) | NO20030483D0 (es) |
| NZ (1) | NZ523982A (es) |
| PE (1) | PE20020264A1 (es) |
| PL (1) | PL204278B1 (es) |
| PT (1) | PT1313500E (es) |
| SK (1) | SK1202003A3 (es) |
| TN (1) | TNSN01116A1 (es) |
| WO (1) | WO2002011751A2 (es) |
| ZA (1) | ZA200300903B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107420042B (zh) * | 2017-09-25 | 2023-03-31 | 中国地质大学（武汉） | 一种基于六自由度并联机构的海底钻机自动调平系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0867676A (ja) * | 1994-03-30 | 1996-03-12 | Eisai Kagaku Kk | 保護アミノチアゾリル酢酸誘導体 |
| US5464616A (en) * | 1994-08-04 | 1995-11-07 | Synphar Laboratories, Ind. | 6β-substituted penicillanic acids as beta-lactamase inhibitors |
| US5686441A (en) * | 1995-08-04 | 1997-11-11 | Syphar Laboratories, Inc. | Penam sulfones as β-lactamase inhibitors |
| FR2755857B1 (fr) * | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| US6187746B1 (en) * | 1997-12-16 | 2001-02-13 | Rhone-Poulenc Rorer S.A. | Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof |
| US6465428B1 (en) * | 1999-08-27 | 2002-10-15 | Aventis Pharma S.A. | Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime |
-
2000
- 2000-08-03 FR FR0010245A patent/FR2812549B1/fr not_active Expired - Fee Related
-
2001
- 2001-07-26 PE PE2001000759A patent/PE20020264A1/es not_active Application Discontinuation
- 2001-08-01 TN TNTNSN01116A patent/TNSN01116A1/fr unknown
- 2001-08-01 AR ARP010103684A patent/AR033992A1/es unknown
- 2001-08-02 DE DE60106463T patent/DE60106463T2/de not_active Expired - Lifetime
- 2001-08-02 CZ CZ2003290A patent/CZ2003290A3/cs unknown
- 2001-08-02 SK SK120-2003A patent/SK1202003A3/sk unknown
- 2001-08-02 AU AU2001284095A patent/AU2001284095B2/en not_active Ceased
- 2001-08-02 IL IL15423701A patent/IL154237A0/xx unknown
- 2001-08-02 AT AT01963045T patent/ATE279204T1/de not_active IP Right Cessation
- 2001-08-02 CN CNB018148573A patent/CN1256982C/zh not_active Expired - Fee Related
- 2001-08-02 EP EP01963045A patent/EP1313500B1/fr not_active Expired - Lifetime
- 2001-08-02 ES ES01963045T patent/ES2230358T3/es not_active Expired - Lifetime
- 2001-08-02 BR BR0112897-3A patent/BR0112897A/pt not_active IP Right Cessation
- 2001-08-02 PL PL365075A patent/PL204278B1/pl not_active IP Right Cessation
- 2001-08-02 AU AU8409501A patent/AU8409501A/xx active Pending
- 2001-08-02 CA CA002418023A patent/CA2418023A1/fr not_active Abandoned
- 2001-08-02 KR KR1020037001575A patent/KR100808715B1/ko active IP Right Grant
- 2001-08-02 DK DK01963045T patent/DK1313500T3/da active
- 2001-08-02 NZ NZ523982A patent/NZ523982A/en not_active IP Right Cessation
- 2001-08-02 MX MXPA03000959A patent/MXPA03000959A/es unknown
- 2001-08-02 JP JP2002517086A patent/JP2004505926A/ja active Pending
- 2001-08-02 HU HU0300682A patent/HU227455B1/hu not_active IP Right Cessation
- 2001-08-02 EA EA200300214A patent/EA007713B1/ru unknown
- 2001-08-02 PT PT01963045T patent/PT1313500E/pt unknown
- 2001-08-02 WO PCT/FR2001/002520 patent/WO2002011751A2/fr active IP Right Grant
- 2001-08-03 US US09/920,810 patent/US7005416B2/en not_active Expired - Lifetime
-
2003
- 2003-01-30 NO NO20030483A patent/NO20030483D0/no not_active Application Discontinuation
- 2003-01-31 ZA ZA200300903A patent/ZA200300903B/en unknown
-
2004
- 2004-02-13 HK HK04101034A patent/HK1058305A1/xx not_active IP Right Cessation
-
2006
- 2006-01-04 US US11/325,919 patent/US20060122103A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100051735A (ko) | 항생제의 투여 방법 | |
| JP5782615B2 (ja) | オリタバンシンの単回用量を用いる治療の方法 | |
| O'Reilly et al. | Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin | |
| Archer et al. | Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies | |
| Capdevila et al. | Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique | |
| Galetto et al. | Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis | |
| AU2001284095B2 (en) | Combinations of dalfopristine/quinupristine with cefpirome | |
| US11766425B2 (en) | Antibiotic combination therapies | |
| US5658887A (en) | Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivatite | |
| US6465428B1 (en) | Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime | |
| US20230364065A1 (en) | Antibiotic combination therapies | |
| Hughes | Antibiotic treatment of chronic bronchitis | |
| CA3022675A1 (en) | Antibacterial compositions | |
| Peerbooms et al. | Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice |